Richard A. Miller MD - 12 Jun 2023 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Reporting relationship: Director
Issuer ticker: BOLT
Reported as of: 12 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2023, 17:18:39 UTC
Prior SEC filing: 03 Apr 2023
Next SEC filing: 08 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ William P. Quinn, Attorney-in-Fact

Key filing fact

Richard A. Miller MD filed Form 4 for Bolt Biotherapeutics, Inc. (BOLT) on 14 Jun 2023.

Key facts

This page summarizes Richard A. Miller MD's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2023, 17:18.

Change

Previous filing in this sequence was filed on 03 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 12 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.